Duration of adjuvant trastuzumab treatment in routine practice

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4585-4588

  Montserrat, Magali ^a   Levêque, Dominique ^a   Barthelemy, Philippe ^a   Bergerat, Jean Pierre ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Adjuvant therapy; Breast cancer; Duration of treatment; Trastuzumab

Indexed keywords

DOCETAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT REFUSAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CARDIOTOXINS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 84867803578     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987. (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005. (Pubitemid 41464705)
4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN and Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005. (Pubitemid 41464706)
5. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawliki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A and Crown J: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283, 2011.
6. Yin W, Jiang Y, Shen Z, Shao Z and Lu J: Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PLoS One 6: e21030, 2011.
7. Danese MD, Lalla D, Brammer M, Doan Q and Knopf K: Estimating recurrences prevented from using trastuzumab in HER-2/neu -positive adjuvant breast cancer in the United States. Cancer 116: 5575-5583, 2010.
8. Spielmann M, Roché H, Delozier T, Canon JC, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL and Penault-Llorca F: Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 27: 6129-6134, 2009.
9. Murray LJ, Ramakrishnan S, O'Toole L, Manifold IH, Purohit OP and Coleman RE: Adjuvant trastuzumab in routine clinical practice and the clinical impact of cardiac monitoring guidelines on treatment delivery. Breast 19: 339-344, 2010.
10. Webster RM, Abraham J, Palaniappan N, Caley A, Jasani B and Barrett-Lee P: Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Br J Cancer 106: 32-38, 2012.
11. di Cosimo S. Heart to heart with trastuzumab: A review on cardiac toxicity. Targ Oncol 6: 189-195, 2011.
12. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Fander M, Helle L, Ingalsuo S, Johansson K, Jää skeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809-820, 2006. (Pubitemid 43290919)
13. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhov M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P and Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377-384, 2010.
14. Gnant M and Steger GG: Dual inhibition of HER2 in breast cancer treatment. Lancet 379: 596-598, 2012.